- Report
- May 2024
- 138 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- June 2024
- 200 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- June 2024
- 200 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- January 2022
- 60 Pages
Global
From €3603EUR$3,950USD£3,080GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1140EUR$1,250USD£975GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1824EUR$2,000USD£1,559GBP
- Report
- May 2022
- 65 Pages
Global
From €1824EUR$2,000USD£1,559GBP
- Report
- May 2022
- 39 Pages
Global
From €1824EUR$2,000USD£1,559GBP
- Report
- May 2022
- 55 Pages
Global
From €1824EUR$2,000USD£1,559GBP
The CNS Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat central nervous system (CNS) lymphoma, a rare type of cancer that affects the brain and spinal cord. These drugs are typically used in combination with other treatments such as radiation and chemotherapy. Commonly used CNS Lymphoma Drugs include rituximab, bendamustine, and temozolomide.
The CNS Lymphoma Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Roche, Novartis, Merck, Pfizer, and Bristol-Myers Squibb. Other companies such as Celgene, Gilead, and AbbVie are also active in the market. Show Less Read more
